Authors’ response to letter to editor Euibeom ShinYifan YuMurali Ramanathan Correspondence 27 May 2024
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment Hinpetch DaungsupawongViroj Wiwanitkit Correspondence 25 May 2024
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel David WangChris JacksonStephen Duffull Correction Open access 14 May 2024
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema Dan SextonHoa Q. NguyenAndy Z. X. Zhu Original Paper Open access 11 May 2024
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies Leonid GibianskyEkaterina Gibiansky Original Paper 03 May 2024
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins Shufang LiuYingyi LiDhaval K. Shah Original Paper 01 May 2024
Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM Euibeom ShinYifan YuMurali Ramanathan Original Paper 24 April 2024 Pages: 187 - 197
Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site Leonid GibianskyChee M. NgEkaterina Gibiansky Original Paper 19 April 2024
A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver and/or kidney dysfunction Xueyong LiYu ChengHongqiang Qiu Original Paper 16 April 2024
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles Deok Yong YoonMichael J. Danielsthe DMD MR Biomarker Steering Committee Original Paper 12 April 2024
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approaches Morgane PhilippSimon BuatoisFrance Mentré Original Paper 09 April 2024
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease Azmi NasserRoberto GomeniJonathan Rubin Original Paper Open access 05 April 2024
Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions Tongtong LiSufeng ZhouFeng Shao Original Paper 30 March 2024
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab Monica SimeoniShuying YangRichard Dimelow Original Paper Open access 29 March 2024 Pages: 289 - 301
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models Alexander JanssenFrank C. Bennisfor the OPTI-CLOT Study Group and SYMPHONY Consortium Original Paper Open access 26 March 2024
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing Jasmine H. HughesJanel Long-BoyleRon J. Keizer Original Paper Open access 23 March 2024 Pages: 279 - 288
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel David WangChris JacksonStephen Duffull Original Paper Open access 19 March 2024
Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling Miriam SchirruHamza CharefFahima Nekka Original Paper 17 March 2024
An industry perspective on current QSP trends in drug development Lourdes Cucurull-Sanchez Original Paper Open access 05 March 2024
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis Nikolaos TsamandourasRuolun QiuTimothy Nicholas Original Paper Open access 03 March 2024 Pages: 265 - 277
Fourteenth American Conference on Pharmacometrics (ACoP14) – Innovation and Diversity: Redefining Pharmacometrics Sihem Ait-Oudhia Editorial 28 February 2024 Pages: 95 - 100
Subgroup identification-based model selection to improve the predictive performance of individualized dosing Hiie SoeorgRiste KalameesTuuli Metsvaht Original Paper 24 February 2024 Pages: 253 - 263
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics Krutika PatidarNikhil PillaiPanteleimon D. Mavroudis Original Paper Open access 24 February 2024
Thoughts on plagiarism and the case against Claudine Gay Peter L. Bonate Editorial 15 February 2024 Pages: 1 - 4
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension Janneke M. BrusseePatricia N. SidhartaAndreas Krause Original Paper 08 February 2024 Pages: 243 - 252
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations Franziska Schaedeli StarkClarisse ChavanneHanna E. Silber Baumann Original Paper Open access 03 February 2024 Pages: 227 - 242
Correction: External control arms for rare diseases: building a body of supporting evidence Artak KhachatryanStephanie H ReadTerri Madison Correction Open access 19 January 2024 Pages: 93 - 93
How drug onset rate and duration of action affect drug forgiveness Elias D. ClarkSean D. Lawley Original Paper 10 January 2024 Pages: 213 - 226
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations Sebastian T. TandarLinda B.S. AulinJ. G. Coen van Hasselt Original Paper 26 November 2023 Pages: 199 - 211
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms Pieter-Jan De SutterElke GasthuysAn Vermeulen Original Paper 12 November 2023
Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model Euibeom ShinMurali Ramanathan Original Paper 11 November 2023 Pages: 101 - 108
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs Hsien-Wei HuangShengjia WuDhaval K. Shah Original Paper 10 November 2023
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach Ari BrekkanRocío Lledo-GarciaElodie L. Plan Original Paper Open access 09 November 2023 Pages: 65 - 75
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model Heinrich J. HuberHitesh B. Mistry Original Paper Open access 06 November 2023 Pages: 169 - 185
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations Amitava MitraJong Bong LeeRajesh Krishna Review Paper 04 November 2023 Pages: 475 - 493
Learning pharmacometric covariate model structures with symbolic regression networks Ylva WahlquistJesper SundellKristian Soltesz Original Paper Open access 21 October 2023 Pages: 155 - 167
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc) Yanke YuMichael E. RothenbergAnnemarie N. Lekkerkerker Original Paper 20 October 2023 Pages: 141 - 153
Prospective approaches to gene therapy computational modeling – spotlight on viral gene therapy Mary P ChoulesPeter L. BonateJared Weddell Original Paper Open access 17 October 2023
Low-dimensional neural ODEs and their application in pharmacokinetics Dominic Stefan BrämUri NahumGilbert Koch Original Paper Open access 14 October 2023 Pages: 123 - 140
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs) Bruna ScheuherKhem Raj GhusingaAlison Betts Original Paper Open access 03 October 2023
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective Peter L. BonateJeffrey S. BarrettHao Zhu Correction 05 September 2023 Pages: 89 - 89
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin Mary P. ChoulesPeiying ZuoPeter Bonate ORIGINAL PAPER Open access 26 August 2023
Training the next generation of pharmacometric modelers: a multisector perspective Peter L. BonateJeffrey S. BarrettHao Zhu Commentary 13 August 2023 Pages: 5 - 31
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study Juanjuan JiangLi XuLei Tian Original Paper 11 August 2023 Pages: 77 - 87
Optimal sample selection applied to information rich, dense data David WangTak HungStephen Duffull Commentary 10 August 2023 Pages: 33 - 37
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies Sanika NawareDavid BussingDhaval K. Shah Original Paper 09 August 2023
Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease Gilles TiraboschiDavid MarchionniFabrice Hurbin Original Paper Open access 03 August 2023 Pages: 461 - 474
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases Hugo GeertsSilke BergelerPiet H. van der Graaf Review Paper 28 July 2023
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory Carla WhiteVivi RottschäferLloyd Bridge Correction Open access 26 July 2023 Pages: 91 - 91
Go beyond the limits of genetic algorithm in daily covariate selection practice D. RonchiE. M. ToscaP. Magni Original Paper Open access 26 July 2023 Pages: 109 - 121
